These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6785454)

  • 1. The effect of mitomycin C on superficial bladder cancer.
    Soloway MS; Murphy WM; DeFuria MD; Crooke S; Finebaum P
    J Urol; 1981 May; 125(5):646-8. PubMed ID: 6785454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
    Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
    Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
    Giesbers AA; Van Helsdingen PJ; Kramer AE
    Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
    Droller MJ; Walsh PC
    J Urol; 1985 Dec; 134(6):1115-7. PubMed ID: 3932686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
    Baker WC; Russo MA; deVere White RW
    Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
    Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
    Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
    Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
    J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical mitomycin C therapy for carcinoma of the bladder.
    Stricker PD; Grant AB; Hosken BM; Taylor JS
    J Urol; 1987 Nov; 138(5):1164-6. PubMed ID: 3118056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin C in superficial bladder cancer: 24-month follow-up.
    Somerville JJ; Newling DW; Richards B; Robinson MR; Smith PH
    Br J Urol; 1985 Dec; 57(6):686-9. PubMed ID: 3936564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
    Stricker PD; Grant AB; Hosken BM; Taylor JS
    J Urol; 1990 Jan; 143(1):34-5; discussion 35-6. PubMed ID: 2104637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsequent tumor analysis of 36 patients who have received intravesical mitomycin C for superficial bladder cancer.
    Soloway MS; Ford KS
    J Urol; 1983 Jul; 130(1):74-8. PubMed ID: 6408268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.